PB272-Kadcyla Combo May Benefit HER2-Positive Breast Cancer Patients, Study Finds

PB272-Kadcyla Combo May Benefit HER2-Positive Breast Cancer Patients, Study Finds
A combination of PB272 (neratinib) and Kadcyla (ado-trastuzumab emtansine) may benefit HER2-positive metastatic breast cancer patients who previously received chemotherapy and another combo treatment, a clinical trial indicates. Results of the FB-10 Phase 1b/2 trial (NCT02236000) revealed that 56 percent of patients saw their tumor shrink or disappear after the combo treatment. The patients had previously received chemo plus a combination of Herceptin (trastuzumab) and Perjeta (pertuzumab). Patients were also able to tolerate the PB272-Kadcyla combo, the trial indicated. The findings were presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington April 1-5. The oral presentation was titled "NSABP FB-10: Phase Ib dose-escalation study evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer." “We are pleased to see the high response rate of the combination of T-DM1 and neratinib in this patient population who were previously treated with both pertuzumab and trastuzumab," Alan H. Auerbach, chief executive officer and president of Puma Biotechnology, said in a press release. "We look forward to completing enrollment in the current cohort and moving this combination into Phase 2 trials.” PB272 is an irreversible tyrosine kinase inhibitor
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.